Pharmacists and pharmacy technicians are set to receive up to £15.9 million over the next four years which will help them thrive in multidisciplinary healthcare teams and enable expansion of frontline staff in primary and community care.
The funding, which is part of the Pharmacy Integration Programme allocation, will improve registered pharmacy professionals' skills, through a range of training
and development opportunities.
The programme is a part of education reform for pharmacy professionals and will allow them to identify career pathways.
Health Education England and NHS England will work in partnership to develop "a formal portfolio recognition process to identify the existing skills, training and experience gained by pharmacists working in primary care, allowing them to work more flexibly and better support GP services", HEE said in a statement today (November 8).
Walgreens Boots Alliance, the American owner of Boots UK, could risk losing billions after a private equity firm interested in buying its UK high street
pharmacy chain valued the retailer at a steep discount, The Telegraph reported on Monday (April 11).
"Buyout funds CVC and Bain indicated that they were willing to pay just £4bn for the business," the newspaper said, adding that "the consortium bowed out of the
running" in March.
The US retail giant Walgreens, which acquired Boots in 2014 for £9bn, has put a £7bn price tag on the UK pharmacy retail chain after selling its wholesale arm,
Alliance Healthcare, last year.
Citing city sources, the newspaper said the low valuation of the pharmacy multiple was "significant" because CVC's UK operations were led by Dominic Murphy, a
Walgreens board member involved with Boots for 15 years.
"He (Murphy) knows where the bodies are buried," the newspaper quoted one City source as stating. A spokesperson for Boots confirmed that CVC and Bain never
lodged a formal offer for the company.
Pharmacy chain Superdrug has introduced what it asserts to be the most affordable private flu vaccinations offered on the UK high street. The vaccinations
will be priced at £8.79 for 17.2 million members of its Ghada , and £16.99 for non-members. The 2023-24 vaccination service is set to become available across 150 of
its stores starting from early September.
Superdrug has taken this step in response to a change in NHS England's inclusion criteria, which has rendered the 12 million individuals aged 50-65 ineligible for
the NHS flu vaccination service, the company said. The company is anticipating heightened demand for private flu vaccinations due to the postponed commencement of
the NHS service and alterations in eligibility for free flu jabs.
"Our waiting list for private flu vaccination services has already exceeded last year's figures, indicating a heightened demand this year," said Ghada Beal,
Superdrug's Healthcare Director. "Providing this service at a more accessible price-point is significant, given the eligibility changes that will impact millions.
Our private flu vaccination services provide a convenient means for individuals to safeguard themselves against flu and its potential complications."
In May, the government's annual flu vaccination programme letter indicated that individuals aged 50 to 64 won't receive free flu vaccinations in the 2023/24
season. Moreover, the NHS plans to delay flu vaccine distribution to October, with the goal of enhancing protection for those aged 65 and older and other eligible
groups during the winter months.
The Royal Pharmaceutical Society (RPS) has re-elected Andrew Carruthers as chair of RPS Scotland Pharmacy Board.
Andrew is a Medicines Governance pharmacist within NHS Greater Glasgow and Clyde, where he has a clinical commitment to Care of the Elderly. Prior to becoming a
pharmacist, he studied Pharmacology at the University of Glasgow, and maintains a keen interest in pharmacokinetics and research.
In his address for the position, he said: "In my second term I want to continue to support and drive the introduction of RPS Ambassadors and the creation of an
online RPS community."
"As a previous RPS local coordinator, I've seen first-hand that RPS Local events are a great forum to formally support the training and development of local
pharmacists. With input from our members and RPS staff we could share learning, inspire, and enable development, and build a supportive online community for the
profession."
He was the RPS Local Co-ordinator for Greater Glasgow and Clyde for 3 years, then he co-opted on to the Scottish Pharmacy Board (SPB) in 2018 and have been an
active and effective member of the board. He was re-elected to the board in 2021 and he stood and was elected as Chair.
The result of the common registration assessment for pharmacists, held jointly by the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of
Northern Ireland (PSNI), have been published with an overall pass rate of 80 per cent.
A total of 2,697 candidates sat the registration assessment in four countries on 29 June and 2,147 candidates passed the assessment.
This summer's pass rate has fallen to 80 per cent compared with the 82 per cent pass rate for the summer 2021 registration assessment, and the 61 per cent pass rate
for the Autumn 2021 registration assessment.
GPhC chief executive Duncan Rudkin said: "We would like to congratulate the successful candidates and we look forward to them joining our register and continuing to
the next stage of their career.
"However, we appreciate that the June registration assessment was a difficult and stressful experience for many - and we are extremely sorry about the problems
faced by a number of candidates on the day.
"For those who did not pass, there is a guide on our website [PDF 255 KB] outlining all the options that may be available, such as provisional registration and
the right to appeal. There are also links to organisations and resources that can provide support with mental health and wellbeing.
The General Pharmaceutical Council (GPhC) has published the results of the common registration assessment for aspiring pharmacists held on 2 November, 2023.
An overall pass rate of 66 per cent was recorded this year, as compared to 56 per cent in 2022 and 61 per cent in 2021.
A total of 1,067 candidates took the registration assessment, held jointly by the GPhC and Pharmaceutical Society of Northern Ireland (PSNI), of which
700 candidates cleared the assessment
In 2022, 937 candidates sat the registration assessment of which 525 passed the assessment.
Commenting on the results, GPhC Director of Education and Standards, Mark Voce, said: "I would like to congratulate all those who passed the November
registration assessment and I look forward to them joining our register to continue to the next stage of their career.
"There will be candidates who unfortunately did not pass the assessment. If this is the case, the information on our website outlines all the possible
options of what to do next.
Labour Party leader Keir Starmer leader has tested positive for Covid-19 for a second time, a spokesperson confirmed on Wednesday (January 5).
Starmer had been due to face prime minister Boris Johnson at a question and answer session in parliament later today. His deputy, Angela Rayner, will take his place, the spokesperson added.
Starmer had tested positive for Covid-19 last October and self-isolated four times after coming into contact with other positive cases on several occasions.
Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.
The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83.
Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs
that could add at least $25 billion in annual sales by the end of the decade.
"The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric.
Biohaven forecast Nurtec sales of $825 million to $900 million in 2022.
Pfizer said it expects the pills to eventually overtake the shots.
Professor Michael Gordon Scott and Professor Charlotte Anne Skitterall have been recognised in the New Year Honours list 2023 for their 'service to pharmacy'.
Professor Scott Director, Medicines Optimisation Innovation Centre was one among the 1,107 people to received MBE for his 'service to pharmacy' in Northern Ireland.
In 1994 he established the first academic practice unit in the province in conjunction with the Queens University of Belfast. In 2004 he was made a fellow of the
Pharmaceutical Society of Northern Ireland. In June 2009 he was made an honorary Professor of Pharmacy Practice at QUB.
Professor Skitterall, Group Chief Pharmacist, Manchester University NHS Foundation Trust received MBE for 'services to Pharmacy'. Last year, she was appointed as a
Fellow of the Royal Pharmaceutical Society. "I think it was awarded in recognition of the work I have done as chair of the National Medicines Optimisation Clinical
Reference Group. I also supported the National Pharmacy Task and Finish Group for Covid Vaccine deployment," she commented.
This year, dozens of NHS staff have been recognised in the New Year Honours list ahead of the health service's 75th birthday.
Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential
bias in the design and use of medical devices.
Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three
areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics.
The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood
oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen
levels in such patients were missed.
However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care.
Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin
tones within the NHS and eliminating racial bias from data sets employed in clinical studies.